Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX, and More

Citigroup upgraded Lockheed Martin to Buy and raised its price target to $582 from $571, changing near-term valuation expectations.

Short-term upside bias; follow-through depends on broader risk appetite and defense-sector tape.

The article provides a concrete rating change and target increase, which typically drives incremental demand and sentiment.

Guggenheim raised Salesforce to Buy with a $228 target, moving it from Neutral and resetting the Street’s stance.

Moderate positive bias over days to weeks; magnitude likely limited without new fundamentals beyond the note.

The text discloses a specific upgrade and target, but no new operating data or guidance.

Guggenheim upgraded ServiceNow to Buy and set a $125 target from Neutral, signaling improved expectations for the platform.

Short-to-medium term supportive; could fade if broader software multiples compress.

Concrete analyst action is provided, but the article lacks thesis details or company-specific new events.

RBC Capital downgraded Dow to Sector Perform and cut its price target to $28 from $51, materially lowering valuation assumptions.

Negative bias; could pressure the stock on any rally as traders reprice the target distribution.

The article includes a substantial target reduction alongside a rating downgrade, which is typically high-impact for sentiment.

Baird initiated Abbott Laboratories with an Outperform rating and a $121 target, introducing a new Street baseline.

Mild-to-moderate upside bias initially; follow-through depends on subsequent research and earnings.

The note is a fresh initiation with a stated target, but no new company data is included.

Wedbush initiated Kratos Defense and Security Solutions with an Outperform rating and a $95 target, adding a new bullish catalyst.

Short-term supportive; likely limited without additional thesis specifics.

The article discloses initiation and target, but provides no operational update.

Wedbush initiated Space Exploration Technologies (SpaceX) with an Outperform rating and a $190 target, per the article’s initiation list.

Low confidence on tradability/impact; treat as low-quality signal for execution.

The article lists a ticker for SpaceX, but SpaceX is not generally known as a US-listed equity; the information may be unreliable.

Jefferies upgraded Abivax to Buy and lifted its target to $158 from $108, changing the risk/reward view for the biotech.

Near-term upside bias; volatility likely high given biotech-specific risk.

Concrete rating/target change is provided, but no trial/clinical datapoint is included.